WinSanTor mission is simple – develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of todays patients heavily burdened by periperal neuropathy.
We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including ‘recycling’ a previously approved safe drug. Phase 1 is complete, and we are now starting phase 2. Our goal is to get drug approval in the U.S. by 2021 and perhaps sooner elsewhere. And by focusing on patient impact rather than the bottom line, we believe we’re creating a new sustainable model for pharma companies based on patient need, not just money.